The Cost-Effectiveness of the SMART Work & Life Intervention for Reducing Sitting Time

Edward Cox 1,* , Simon Walker 1 , Charlotte L. Edwardson 2,3 , Stuart J. H. Biddle 4 , Alexandra M. Clarke-Cornwell 5,6 , Stacy A. Clemen 7,8 , Melanie J. Davies 2,3,7 , David W. Dunstan 8,9 , Helen Eborall 10,11 , Malcolm H. Granat 5 , Laura J. Gray 12, Genevieve N. Healy 12, Benjamin D. Maylor 2 , Fehmidah Munir 6, Thomas Yates 2,3 and Gerry Richardson 1

1 Centre for Health Economics, University of York, York YO10 5DD, UK
2 Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, LE5 4PW, UK
3 NIHR Leicester Biomedical Research Centre, Leicester LE5 4PW, UK
4 Centre for Health Research, University of Southern Queensland, Springfield, QLD 4300, Australia
5 School of Health & Society, University of Salford, Salford M6 6PU, UK
6 School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough LE11 3TU, UK
7 Leicester Diabetes Centre, University Hospitals of Leicester, Leicester LE5 4PW, UK
8 Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia
9 Baker-Deakin Department Lifestyle and Diabetes, Deakin University, Melbourne, VIC 3004, Australia
10 Department of Health Sciences, University of Leicester, Leicester LE1 7RH, UK
11 Deanery of Molecular, Genetic and Population Health Sciences, The University of Edinburgh, Edinburgh EH16 4UX, UK
12 School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, QLD 4067, Australia

* Correspondence: edward.cox@york.ac.uk

Abstract: Sedentary behaviours continue to increase and are associated with heightened risks of morbidity and mortality. We assessed the cost-effectiveness of SMART Work & Life (SWAL), an intervention designed to reduce sitting time inside and outside of work, both with (SWAL-desk) and without (SWAL-only) a height-adjustable workstation compared to usual practice (control) for UK office workers. Health outcomes were assessed in quality-adjusted life-years (QALY) and costs in pound sterling (2019–2020). Discounted costs and QALYs were estimated using regression methods with multiply imputed data from the SMART Work & Life trial. Absenteeism, productivity and wellbeing measures were also evaluated. The average cost of SWAL-desk was £228.31 and SWAL-only £80.59 per office worker. Within the trial, SWAL-only was more effective and costly compared to control (incremental cost-effectiveness ratio (ICER): £12,091 per QALY) while SWAL-desk was dominated (least effective and most costly). However, over a lifetime horizon, both SWAL-only and SWAL-desk were more effective and more costly than control. Comparing SWAL-only to control generated an ICER of £4985 per QALY. SWAL-desk was more effective and costly than SWAL-only, generating an ICER of £13,378 per QALY. Findings were sensitive to various worker, intervention, and extrapolation-related factors. Based on a lifetime horizon, SWAL interventions appear cost-effective for office-workers conditional on worker characteristics, intervention cost and longer-term maintenance in sitting time reductions.

Keywords: cost-effectiveness; SMART; sedentary behaviour; healthy habits; standing desks

1. Introduction

Sedentary behaviours continue to increase and are associated with heightened risks of several chronic diseases and all-cause mortality [1]. In the United Kingdom (UK), sedentary behaviours are known to contribute to over £700 million in National Health Service (NHS) costs and 69,276 deaths in 2016 [2]. The COVID-19 pandemic has further exacerbated sedentary behaviours and their consequences for public health [3,4], prompting policy
interest in public health strategies that promote safe physical activity and reduce sedentary behaviours [5,6].

In line with the global context, UK office workers are a highly sedentary population, spending approximately 70–85% of their time at work sitting [7–9]. With over half of the UK working population economically active and predominately working in sedentary or light physical activity occupations, workplaces are an ideal setting for interventions designed to reduce daily sitting. Acute experimental studies have shown strategies designed to promote frequent bouts of light-intensity movement can improve markers of cardiometabolic and musculoskeletal health [10–16], while meta-analytic studies have found the relationship between sedentary time and adverse outcomes are most pronounced at the highest levels of inactivity [17–19]. Both public- and private-sector organisations need to identify and manage the wider risks of sedentary behaviour to people’s health. Embracing a preventive health model stands to improve office-workers’ physiological and psychological health, alleviate public healthcare requirements, and assist in the development of a resilient and productive workforce [20,21].

The SMART Work & Life programme is a multicomponent intervention, designed to reduce ambulatory office workers’ sitting time inside and outside work [22]. The intervention includes organisational, environmental, and group/individual level behaviour change strategies, delivered by workplace champions. The programme’s effectiveness was tested within a cluster randomised controlled trial, which demonstrated that SMART Work & Life successfully reduced daily sitting time compared to a control group. This economic analysis aims to consider the cost-effectiveness of the SMART Work & Life intervention, delivered with and without a height-adjustable workstation, using evidence from the SMART Work & Life cluster randomised controlled trial. By estimating the health benefits and costs associated with SMART Work & Life, we can aid the development of this and other public health initiatives while ensuring resources are allocated only to those interventions which maximise population health [23,24].

2. Materials and Methods

2.1. Overview

The cost-effectiveness of the SMART Work & Life (SWAL) intervention with (SWAL-desk) and without (SWAL-only) a height-adjustable workstation was evaluated in two parts: (i) a within-trial analysis considering costs and outcomes estimated over the trial period (12 months); and (ii) a lifetime horizon decision analytic modelling analysis incorporating longer-term mortality benefits from reductions in sedentary behaviour over a person’s lifetime.

Intervention and healthcare costs were measured in UK pounds sterling (2019–2020) from a public sector perspective [25]. Office-worker outcomes included quality adjusted life-years (QALY), absenteeism days, measures of productivity, psychological health, job satisfaction, and work engagement [7,26]. In line with UK guidelines, costs and QALYs were discounted at 3.5% per annum [25]. Within-trial costs and QALYs were estimated using regression methods to control for participant co-variables. Long-term outcomes were modelled using contemporary estimates of the dose–response relationship between sedentary time and all-cause mortality [18,19]. Cost-effectiveness results are presented as incremental cost-effectiveness ratios and incremental net-health benefits at cost-effectiveness thresholds relevant to UK decision-making (£15,000, £20,000 and £30,000 per QALY) [24]. Missing cost, QALY and absenteeism data were imputed [27,28]. Probabilistic sensitivity analysis was used to estimate decision uncertainty. Deterministic scenario, sensitivity, and threshold analyses further explored the impacts surrounding key model assumptions.

2.2. SMART Work & Life Trial

The SMART Work & Life trial was a three-arm cluster randomised controlled trial (n = 756) that evaluated the effectiveness of SWAL-desk (n = 240) and SWAL-only (n = 249) at reducing daily sitting time in office workers compared to a control (usual practice)
SWAL includes organisational, environmental (e.g., relocating waste bins, printers), and group/individual (e.g., education, action planning, goal setting, addressing barriers, group coaching, sitting less challenges, self-monitoring) level behaviour change strategies, facilitated by workplace champions. Office groups within local councils across three areas of England were randomised to one of three arms: SWAL-desk, SWAL-only, or control. Randomisation was stratified by council area (Leicester, Liverpool, and Greater Manchester) and cluster size (<10 and ≥10 participants). Trial participants consisted of consenting, English speaking, non-pregnant and mobile (able to walk unassisted) adult office workers (≥60% full time equivalent) nested within shared office spaces [26]. Follow-up measurements were taken at 3 and 12 months with activity data recorded using a thigh-worn accelerometer-based device. Further details about SWAL and the trial are available elsewhere [29].

2.3. Resource Use and Costs

Costs for each trial participant were categorised into (i) intervention-related; (ii) health-related; and (iii) absenteeism-related. Intervention-related costs were calculated on an intention-to-treat (ITT) basis and comprised: training workplace champions and general staff (including staff time costs); managers correspondence time; office motivational materials; and the procurement and installation of height-adjustable workstations. Health-related costs were assessed from a public-perspective and equated to the number of self-reported resources consumed during the trial multiplied by their respective unit costs. Linear interpolation was used to populate resource use data not recorded between 3-month and 9-month follow-up. Unit costs were obtained from a variety of published UK sources (Supplemental Table S1) and were inflated to UK pounds sterling 2019–2020 where necessary [30,31]. Absenteeism-related costs were calculated using the median daily UK salary (2019) [32].

2.4. Outcomes

The primary health outcome for office-workers was expressed by QALYs, a generic measure of health where one QALY represents a year in perfect health [24]. Within-trial health-related quality of life (HRQoL) was measured using EQ-5D-5L responses, a descriptive instrument defined by five health dimensions (mobility; self-care; usual activities; pain/discomfort and anxiety/depression) assessed over five severity levels (no problems, slight problems, moderate problems, severe problems and extreme problems) [33]. As recommended in NICE guidelines, EQ-5D-5L responses were mapped onto those applicable to the UK EQ-5D-3L value set to generate HRQoL weights [25,34]. HRQoL weights from the UK EQ-5D-5L value set were considered as a scenario. Observed within-trial QALYs were calculated using an area under the curve approach with linear interpolation between time points. QALYs beyond the trial were calculated by the decision analytic model. Measures of stress, wellbeing, absenteeism, and work performance, satisfaction and engagement were considered descriptively.

2.5. Analysis

2.5.1. Within-Trial Analysis

Within-trial costs and QALYs were estimated from derived observations (see Sections 2.2 and 2.3) for each treatment using generalised linear regression models that controlled for age, gender, ethnicity (White vs. Other), body mass index (BMI), site area (Leicester; Salford; Liverpool) and cluster size (small < 10; large ≥ 10) [35]. QALY and absenteeism regression analyses also controlled for baseline EQ-5D scores and absenteeism days, respectively [36]. Costing and absenteeism regressions used a log-link transformation and gamma family form to account for the bounded right-skewed nature of the dependant variable [37]. QALY regressions applied ordinary least squares. Multi-level regression models that considered residual components at the site-level hierarchy were considered in scenario analyses [38].
2.5.2. Decision Analytic Model and Long-Term Cost-Effectiveness

Outcomes beyond the trial were estimated using a two-state alive-dead Markov-model with costs and QALYs discounted at 3.5% per annum, and 1.5% in a scenario [25,39]. In the alive-state, individuals experience HRQoL equal to age-adjusted English population norms and accrue no costs [40]. A scenario considered age-specific NHS costs for the alive state [41]. For control, transitions to the death-state were assumed to follow age- and sex-adjusted English general population mortality rates [42]. Transitions were adjusted by common all-cause mortality hazard ratios (i.e., those irrespective of participant characteristics) associated with each SWAL-interventions’ reduction in sedentary time, as reported in Ekelund et al.’s accelerometer-measured meta-analysis (see Supplemental Figure S1) [18]. Hazard ratios from Patterson et al.’s (2018) broader meta-analysis (including non-objective sedentary measurements) were considered as a scenario [19]. In line with previous economic evaluations, treatment-effects on sedentary time were assumed to exponentially decline at a 50% decay rate per annum (i.e., every year the reduction in sedentary time associated with SWAL interventions is halved) [43–46]. Alternative exponential decay rates and a linear decay rate of 20% per annum were explored in scenario and sensitivity analyses [47].

2.5.3. Statistical Methods

Missing trial cost, QALY, and absenteeism data were imputed using a multi-level model to account for heterogeneity between sites and controlled for all the covariates considered in the within-trial regression models. [27]. Estimates generated across 20 imputed datasets were combined using Rubin’s Rules [48,49]. Imputed QALYs were bounded at one and costs and absenteeism days were bounded to positive values. Decision uncertainty was propagated using Monte Carlo simulation assuming normality in sedentary times and treatment effects and multivariate normality of regression coefficients [50]. Uncertainty in mean cost, QALY, and cost-effectiveness estimates was reported via 95% credible intervals and probabilities of being most costly, effective, and cost-effective.

2.5.4. Economic Analysis

Cost-effectiveness was assessed over the trial period (12 months) and over a lifetime horizon using incremental cost-effectiveness ratios (ICERs) and incremental net health benefits (INHBs) [24]. ICERs represent the incremental cost per additional QALY of a strategy compared with the next best alternative; INHB the SWAL-related health gain relative to control less the health opportunity cost from additional expenditure as defined by the cost-effectiveness threshold (i.e., the health forgone elsewhere from resources not being available for other health generating purposes). INHB and the probability of being cost-effective are presented at three relevant UK threshold values: £15,000, £20,000 and £30,000 per QALY [25,51,52]. ICERs below the threshold are deemed cost-effective (compared to the next best relevant comparator); a positive INHB infers cost-effectiveness compared to control.

Additional scenario analyses included alternate worker age profiles, removing estimated within-trial public sector costs and QALY differentials between arms, and a broader multi-sectoral perspective including private absenteeism costs. When including private absenteeism costs, two scenarios were considered; one where they were weighted equally with public sector costs and another where private sector costs are valued at a lower rate based on evidence of the higher opportunity costs associated with public resources (private costs weighted four times lower) [51–54]. Sensitivity analyses considered how changes in age, treatment decay rates, treatment costs, and treatment-associated reductions in sitting times impacted the INHB of each SWAL intervention compared to control.
3. Results
3.1. Missing Data
Over the course of the trial, the degrees of data completion for the resource use, EQ-5D-5L and absenteeism follow-up data ranged between 61.8–83.5%, 69.0–93.0% and 65.6–87.4%, respectively. Participant characteristics are reported elsewhere [26].

3.2. Outcomes
SWAL-desk and SWAL-only were associated with 63.7- and 22.2 min per day less sitting time compared to the control group at 12-month follow-up, respectively. Imputed within-trial EQ-5D-5L scores, mapped EQ-5D-3L values and associated QALY outcomes were broadly comparable across the trial arms (Supplementary Table S2). When controlling for participant covariates, QALYs were highest for SWAL-only followed by the control arm and SWAL-desk (Supplementary Table S3). The number of employee-reported sick days were similar across the comparators, albeit with temporal changes more favourable for control relative to SWAL-related interventions. Modest improvements in stress and wellbeing scores were observed, whilst no marked differences in job satisfaction, job performance, and measures of work engagement were found (Supplementary Table S4). Controlling for baseline values and participant covariates, absenteeism days were highest for SWAL-desk followed by SWAL-only and control (Supplementary Table S5). At model baseline (12-month follow-up), reductions in sitting time for SWAL-desk and SWAL-only translated into 23.8% and 10.5% reductions in the relative-risk of all-cause mortality compared to control, respectively.

3.3. Resource Use and Costs
The average intervention cost per ITT individual was £228.31 and £80.59 for SWAL-desk and SWAL-only, respectively (Supplementary Table S6). Healthcare resource use was broadly balanced between trial arms (Supplementary Table S7). Imputed within-trial healthcare costs were lowest for SWAL-desk (£541.24) compared to SWAL-only (£672.58) and control (£658.78). When controlling for participant covariates, healthcare costs were highest in the control arm, followed by SWAL-only and SWAL-desk (Supplementary Table S8). Imputed absenteeism costs were highest for SWAL-desk (£211.58) followed by SWAL-only (£184.48) and control (£139.97). This cost ordering was maintained when controlling for baseline values and participant covariates (Supplementary Table S5).

3.4. Economic Analysis
3.4.1. Cost-Effectiveness
Inputs used in the cost-effectiveness analysis are reported in Supplementary Table S9 and Supplementary Figures S1–S3. Table 1 displays the adjusted within-trial and lifetime horizon cost, QALY and cost-effectiveness findings. The within-trial analysis found SWAL-desk to be dominated by both SWAL only and control (i.e., SWAL-desk being the most costly and the least effective alternative). SWAL-only was more costly and effective than control with an ICER of £12,091 per QALY; an INHB range of 0.0011–0.0025; and a probability of being cost-effective ranging between 42.3–43.5% (for a £15,000–£30,000 per QALY threshold range). The lifetime horizon analysis found SWAL-desk to be the most costly and effective (due to reductions in sedentary time); control the least costly and least effective; and SWAL-only the second-most costly and effective. SWAL-only generated an ICER of £4985 per QALY; an INHB range 0.007–0.008; and a probability of being cost-effective range 36.4–38.8% (for a £15,000–£30,000 per QALY threshold range). SWAL-desk was cost-effective compared to SWAL-only at the threshold values considered (ICER: £13,378 per QALY; INHB range 0.007–0.011; probability of being cost-effective range: 44.8–52.7%). The considerable overlap in the credible intervals for costs and QALY between alternatives suggests a significant level of uncertainty.
Table 1. Base case within-trial and lifetime cost-effectiveness results.

| Trial horizon          | Costs (95% CI) | QALYs (95% CI) | ICER | Incremental Net Health Benefit (95% CI) |
|------------------------|----------------|----------------|------|----------------------------------------|
|                        | [P (Most Costly)] | [P (Most Effective)] | k = £15,000 | k = £20,000 | k = £30,000 |
| Control                | £642.06          | 0.84243        | -    | -                                      | -                                      |
|                        | (505.47, 798.4)  | (0.82221, 0.8642) | [0.272] | [0.398] | [0.373] | [0.337] |
| SWAL-only              | £691.19          | 0.84649        | £12,090.73 | -0.024, 0.025 | -0.022, 0.025 | -0.021, 0.025 |
|                        | (563.3, 846.93)  | (0.8265, 0.86585) | [0.442] | [0.423] | [0.432] | [0.435] |
| SWAL-desk             | £747.60          | 0.84187        | Dominated | -0.008 | -0.007 | -0.007 |
|                        | (641.42, 871.14) | (0.82246, 0.86006) | [0.286] | [0.179] | [0.386] | [0.328] |
| Life-time horizon      | Costs (95% CI) | QALYs (95% CI) | ICER | Incremental Net Health Benefit (95% CI) |
|                        | [P (Most Costly)] | [P (Most Effective)] | k = £15,000 | k = £20,000 | k = £30,000 |
| Control                | £48,295.50       | 17.79359       | -    | -                                      | -                                      |
|                        | (507.14, 798.4)  | (17.7737, 17.81535) | [0.085] | [0.164] | [0.139] | [0.109] |
| SWAL-only              | £48,361.39       | 17.80344       | £4984.86 | -0.019, 0.032 | -0.017, 0.032 | -0.015, 0.032 |
|                        | (563.3, 846.93)  | (17.78297, 17.82346) | [0.216] | [0.336] | [0.388] | [0.364] |
| SWAL-desk             | £48,444.07       | 17.80766       | £13,377.90 | -0.024, 0.041 | -0.023, 0.042 | -0.021, 0.043 |
|                        | (641.42, 868.39) | (17.78785, 17.82522) | [0.699] | [0.584] | [0.448] | [0.485] |

CI: Credible interval; P: Probability; k = Cost-effectiveness threshold; ICER: Incremental cost-effectiveness ratio.

3.4.2. Scenario Analyses

Table 2 presents the results from the scenario analyses. The cost-effectiveness of SWAL interventions improved with lower treatment decay rates, suggesting that the longer the maintenance of the sitting reduction, the greater the benefits. For older individuals, the cost-effectiveness of the intervention improved as a result of greater absolute reductions in mortality. Using alternative estimates of impacts of sitting time on all-cause mortality resulted in SWAL-desk being dominated. Other scenarios had minimal impact on our cost-effectiveness findings.

Table 2. Scenario analyses.

| Lifetime costs                        | Costs | QALYs | ICER | EQ-SD-5L preference values—lifetime horizon |
|---------------------------------------|-------|-------|------|---------------------------------------------|
| Control                               | £48,295.50 | 17.79359 | -    | £642.06 | 17.82590 |
| SWAL                                  | £48,361.39 | 17.80341 | £6706 | SWAL | £691.19 | 17.83591 | £4908 |
| SWAL-desk                             | £48,444.07 | 17.80778 | £18,956 | SWAL-desk | £747.60 | 17.84282 | £8164 |

Linear efficacy decay (20% per annum) 1.5% discount rate

| Linear efficacy decay (20% per annum) 1.5% discount rate |
|----------------------------------------------------------|
| Control | £542.06 | 17.79359 | £587.42 | £542.06 | 17.79359 |
| SWAL    | £691.19 | 17.80373 | £668.01 | SWAL    | £691.19 | 17.80373 | £668.01 |
| SWAL-desk | £747.60 | 17.80787 | £44,597 | SWAL-desk | £747.60 | 17.80787 | £44,597 |

70% efficacy decay (per annum) No differential within-trial cost or QALYs estimates

| 70% efficacy decay (per annum) No differential within-trial cost or QALYs estimates |
|---------------------------------------|---------------------------------------------|
| Control | £542.06 | 17.79359 | Control | £642.06 | 17.79359 |
| SWAL    | £691.19 | 17.80373 | SWAL    | £691.19 | 17.80373 |
| SWAL-desk | £747.60 | 17.80787 | SWAL-desk | £747.60 | 17.80787 |

60% efficacy decay (per annum) 1.5% discount rate

| 60% efficacy decay (per annum) 1.5% discount rate |
|---------------------------------------|---------------------------------------------|
| Control | £542.06 | 17.79359 | Control | £642.06 | 17.79359 |
| SWAL    | £691.19 | 17.80373 | SWAL    | £691.19 | 17.80373 |
| SWAL-desk | £747.60 | 17.80787 | SWAL-desk | £747.60 | 17.80787 | £44,597 |
Table 2. Cont.

| Costs         | QALYs     | ICER     | Costs         | QALYs     | ICER     |
|---------------|-----------|----------|---------------|-----------|----------|
| 40% efficacy decay (per annum) |           |          |               |           |          |
| 30 years-old  |           |          |               |           |          |
| Control       | £642.06   | 17.79359 | Control       | £744.01   | 21.18629 |
| SWAL          | £691.19   | 17.80520 | £4231 SWAL    | £783.76   | 21.19302 |
| SWAL-desk     | £747.60   | 17.81197 | SWAL-desk     | £826.24   | 21.19101 |
| 30% efficacy decay (per annum) |           |          |               |           |          |
| 40 years-old  |           |          |               |           |          |
| Control       | £642.06   | 17.79359 | Control       | £667.96   | 18.87570 |
| SWAL          | £691.19   | 17.80781 | £3455 SWAL    | £716.39   | 18.88404 |
| SWAL-desk     | £747.60   | 17.81906 | SWAL-desk     | £770.86   | 18.88595 |
| 20% efficacy decay (per annum) |           |          |               |           |          |
| 50 years-old  |           |          |               |           |          |
| Control       | £642.06   | 17.79359 | Control       | £603.97   | 16.03678 |
| SWAL          | £691.19   | 17.83461 | £2407 SWAL    | £655.99   | 16.05092 |
| SWAL-desk     | £747.60   | 17.83461 | SWAL-desk     | £718.06   | 16.05774 |
| 10% efficacy decay (per annum) |           |          |               |           |          |
| 60 years-old  |           |          |               |           |          |
| Control       | £642.06   | 17.79359 | Control       | £550.85   | 12.72221 |
| SWAL          | £691.19   | 17.83321 | £1080 SWAL    | £602.53   | 12.74258 |
| SWAL-desk     | £747.60   | 17.88543 | SWAL-desk     | £671.68   | 12.76031 |
| 0% efficacy decay (per annum) |           |          |               |           |          |
| 70 years-old  |           |          |               |           |          |
| Control       | £642.06   | 17.79359 | Control       | £504.50   | 9.05734  |
| SWAL          | £691.19   | 17.99396 | £209 SWAL     | £560.21   | 9.08821  |
| SWAL-desk     | £747.60   | 18.26384 | SWAL-desk     | £635.86   | 9.12269  |
| Patterson et al. [19] associated all-cause mortality risks | Male | | Female | | |
| Control       | £642.06   | 17.79359 | Control       | £478.49   | 17.30132 |
| SWAL          | £691.19   | 17.79834 | £10,342 SWAL  | £534.78   | 17.31366 |
| SWAL-desk     | £747.60   | 17.94949 | SWAL-desk     | £613.77   | 17.32035 |
| Absenteeism cost inclusive (weighted 25% to public costs) | | | | |
| Control       | £675.30   | 17.79359 | Control       | £726.83   | 17.99817 |
| SWAL          | £726.96   | 17.80344 | £5245 SWAL    | £765.16   | 18.00801 |
| SWAL-desk     | £791.74   | 17.80766 | SWAL-desk     | £810.88   | 18.01039 |
| Absenteeism cost inclusive (weighted equal to public costs) | | | | |
| Control       | £759.81   | 17.79359 | Control       | £726.83   | 17.99817 |
| SWAL          | £833.77   | 17.80344 | £7509 SWAL    | £765.16   | 18.00801 |
| SWAL-desk     | £922.12   | 17.80766 | SWAL-desk     | £810.88   | 18.01039 |

3.4.3. Sensitivity and Threshold Analyses

Findings were highly sensitive to the treatment efficacy decay rate and worker age (Figure 1). SWAL-only had positive INHB across all decay rates (0–90%), study ages (30–70 years-old) and for any level of sitting-time reduction (due to modest within-trial gains in HRQoL). SWAL-only remained cost-effective at programme costs of £191 (£349) per employee at a £15,000 (£30,000) per QALY threshold. SWAL-desk had positive INHB (vs. control) at decay rates ≤ 88.4% (≤ 100%), ≥ 33 years of age, and for ≥ 29 min (≥ 15 min) reductions in sitting time at a £15,000 (£30,000) per QALY threshold. The INHB was highest for SWAL-desk at decay rates below 49.8% (61.0%), ages ≥ 44 (≥ 40) years and incremental (desk-related) costs relative to SWAL-only of £146 (£202) at a £15,000 (£30,000) per QALY threshold. Sensitivity analyses surrounding treatment efficacy decay rates and worker ages at thresholds £20,000 and £30,000 per QALY are reported in Supplementary Figures S4 and S5.
3.4.3. Sensitivity and Threshold Analyses

Findings were highly sensitive to the treatment efficacy decay rate and worker age (Figure 1). SWAL-only had positive INHB across all decay rates (0–90%), study ages (30–70 years-old) and for any level of sitting-time reduction (due to modest within-trial gains in HRQoL). SWAL-only remained cost-effective at programme costs of £191 (£349) per employee at a £15,000 (£30,000) per QALY threshold. SWAL-desk had positive INHB (vs. control) at decay rates ≤8.4% (≤100%), ≥33 years of age, and for ≥29 min (≥15 min) reductions in sitting time at a £15,000 (£30,000) per QALY threshold. The INHB was highest for SWAL-desk at decay rates below 49.8% (61.0%), ages ≥44 (≥40) years and incremental (desk-related) costs relative to SWAL-only of £146 (£202) at a £15,000 (£30,000) per QALY threshold. Sensitivity analyses surrounding treatment efficacy decay rates and worker ages at thresholds £20,000 and £30,000 per QALY are reported in Supplementary Figures S4–S5.

Figure 1. Sensitivity analyses: (a) Incremental net health benefits for alternative treatment decay profiles at a cost-effectiveness threshold of £15,000 per QALY; (b) Incremental net health benefits for alternative age profiles at a cost-effectiveness threshold of £15,000 per QALY.

4. Discussion

4.1. Key Findings

Results of this study suggest both SWAL interventions are potentially cost-effective, with SWAL-only appearing cost-effective over the trial period and over a lifetime horizon compared to control, whereas SWAL-desk only appeared cost-effective using a lifetime horizon (versus control and SWAL-only). The cost-effectiveness of SWAL-only was predicated on immediate within-trial gains in HRQoL and longer-term benefits from reductions in sitting time. The overall lifetime cost-effectiveness of SWAL-desk resulted from moderate within-trial health-related cost savings and longer-term benefits from reductions in sitting time. The cost-effectiveness of both SWAL-interventions was, however, sensitive to treatment-associated within-trial cost and HRQoL impacts, participant age, maintenance of the sitting reduction, the mortality risks associated with sedentary behaviour, and intervention costs. Compared to control, SWAL-desk was associated with 14.07 incremental discounted QALYs per 1000 employees enrolled, at a cost of £105,542 from a public per-
spective. Compared to SWAL-only, SWAL-desk could be considered cost-effective from the public perspective provided desk-related costs fall below £202 and those additional reductions in sedentary time associated with its application are adequately maintained (≥39% per annum).

4.2. Previous Findings

Munir et al.’s cost–benefit analysis of SMArT Work, an earlier iteration of the SWAL programme, found the intervention improved worker self-perceived productivity and was deemed cost-effective from an organisational perspective [21]. The SWAL interventions however, found no meaningful changes in worker productivity. Gao et al.’s economic evaluation of ‘Stand up Victoria’, another multi-component intervention designed to reduce sitting time at work in desk-based staff, found the intervention was associated with reduced workplace sitting time, no significant benefits in absenteeism or self-reported HRQoL, increased costs, and improved long-term health outcomes [47]. ‘Stand up Victoria’ was deemed cost-effective over a lifetime horizon in the Australian context although results were highly sensitive to the maintenance of the reduction in sitting time. The intervention costs, study findings and conclusions are broadly comparable with those found for SWAL-desk. Michaud et al.’s within-trial cost-effectiveness analysis of ‘Stand and Move at Work’ with (STAND+) versus without (MOVE+) a standing desk, found STAND+ achieved significant reductions in sitting times (47.7 min daily) and improvements in self-reported HRQoL (0.013 EQ-5D score) at a comparable non-annuitized cost ($375) to SWAL-desk (£229) [55]. STAND+ was deemed cost-effective in the US context, despite not being associated with improvements in light-intensity physical activity, productivity or absenteeism.

In line with our study findings, there is limited evidence that SWAL or similar workplace interventions improve employee absenteeism. Nevertheless, workplace interventions generally appear cost-effective, either as a result of health gains from reductions in sedentary time [47,56] and/or improvements in worker HRQoL [55], or via improvements in workplace productivity [21] or presenteeism [57]. Our study reinforced cost-effectiveness via health gains from reductions in sitting time. As reported in Nguyen et al.’s recent systematic literature review, cost-effectiveness evidence of sedentary behaviour reduction interventions in workplaces is limited, but appears broadly consistent [58].

4.3. Strengths and Limitations

Strengths of this study include the application of accelerometer measured treatment-specific sedentary times from a randomised controlled trial; a relatively large sample of diverse UK office workers from which costs were compiled using relevant UK costing sources; HRQoL from a validated instrument; and sedentary-associated all-cause mortality risks aligned to contemporary, robust and objective estimates [18]. In addition, study methodology was consistent with NICE methodological guidance, and the robustness of study results were tested using a wide range of scenario, sensitivity and threshold analyses [25]. All these factors support the validity of the findings observed in this study.

Limitations include the acknowledgement that the estimated within-trial treatment effects on costs and outcomes were highly uncertain and the trial was not powered to detect for such differences. Furthermore, common average treatment-effects and sedentary-associated all-cause mortality risks may overgeneralise the impacts treatments have on the consequences of sedentary behaviour across office-workers. We also applied a narrow scope of the longer-term health benefits associated with changes in sedentary behaviour were captured (i.e., all-cause mortality only) and the base case decay rate in treatment efficacy was unknown and based on those chosen by analysts in previous studies [43–46] rather than empirical data. Other limitations include: the constant sedentary times assigned to control, and those which SWAL-interventions converge to, ignore potential dynamics over-time; intervention costs did not consider potential costs beyond the trial (e.g., equipment maintenance, training and staff work time); and the trial’s setting and exclusion criteria could have limited the generalisability of our findings to
other applicable contexts. Thus, conclusions regarding the cost-effectiveness of the SWAL programmes must be interpreted with caution.

4.4. Policy Implications

Compared to usual practice, our analysis forecasts a 9.85 and 14.07 incremental discounted QALY gain at a public cost of £49,130 and £105,542 for every 1000 office workers enrolled onto SWAL-only and SWAL-desk, respectively. These findings should help to inform resource allocation priorities, with potential implications to the health of office-workers. The extent to which SWAL interventions pose a cost-effective investment in public health is, however, uncertain and may differ in practice from those reported in our analysis for several reasons. First, the expected cost of delivering SWAL-only or SWAL-desk is subject to several market and contextual factors. Changes in the prices of constituent elements (e.g., desks, materials, training), economies of scale, local office factors (e.g., shared desks, staff time costs, remote working, office culture, work demands) and broader programme alterations (e.g., those necessary to facilitate wide-scale roll-out) all may significantly change the average cost of programme delivery. Second, health gains are contingent on participant characteristics and engagement which likely vary across settings. Workers that benefit most from reductions in sedentary time and those receptive and motivated to maintain sedentary behaviour changes appear to be key sub-groups to consider. Thus, a targeted approach to implementing SWAL-interventions may be warranted, with those office teams with older staff, pre-existing conditions that benefit from activity, and those exposed to prolonged periods of sitting prioritised. Third, a wider perspective and further extrapolation of potential cost and HRQoL impacts from SWAL-programmes (e.g., long-term mitigation of non-fatal events, productivity, absenteeism) would give a more comprehensive account of the implications SWAL-programmes have on office-workers and their employers. Finally, cost-sharing arrangements and private procurements may distribute intervention costs more broadly, meaning sizeable public health gains may be achievable at a lower average public cost.

The cost-effectiveness of the SWAL programmes could not be demonstrated exclusively from an employer’s perspective. In contradiction with similar economic evaluations, moderate rises in absenteeism and largely inconsistent differences in worker performance, productivity and satisfaction suggested no meaningful positive changes in employer outcomes compared to usual services [47,57]. Nevertheless, employers may want to promote employee health per se and be interested in broader outcomes not measured in this analysis, including positive work environment, staff turnover, and company perception.

5. Conclusions

Evidence from the SMART Work & Life trial and recent empirical findings of the all-cause mortality risks from sedentary behaviour suggests both SWAL interventions could be considered a cost-effective strategy from a public perspective for promoting the health of office workers in the UK. Study findings stress the importance of cost containment, maintaining sedentary behaviour reductions over time, and prioritisation of those individuals who stand to benefit the most from reductions in sedentary behaviour. Future research can go further by considering individual- and office-level mediators (factors which may explain the underlying mechanisms of treatment benefit), empirical measures of long-term effectiveness, sedentary behaviour dynamics, distributional cost-effectiveness (concerning the equity in the distribution of costs and effects), and modelling the competing chronic disease risks associated with sedentary behaviours.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijerph192214861/s1, Figure S1: Ekeland et al interpolated hazard ratios; Figure S2: Sedentary time modelled for each comparator; Figure S3: Hazard ratios associated with the sedentary time modelled for each comparator; Figure S4: Incremental net health benefits for alternative age and treatment decay profiles at a cost-effectiveness threshold of £20,000 per QALY; Figure S5: Incremental net health benefits for alternative age and treatment decay profiles at a
cost-effectiveness threshold of £30,000 per QALY; Table S1: Unit costs; Table S2: Imputed HRQoL, QALY and absenteeism by treatment arm and follow-up period; Table S3: Base case QALY regression – ordinary least squares regression; Table S4: Complete case secondary outcomes; Table S5: Base case absenteeism days regression-generalised linear model (family~gamma; link-log); Table S6: Intervention costs; Table S7: Complete case within-trial costs by treatment arm and resource category; Table S8: Base case health resource cost regression – generalised linear model (family~gamma; link-log); Table S9: Model parameters.

Author Contributions: C.L.E., S.J.H.B., M.J.D., D.W.D., G.N.H., L.J.G., T.Y., F.M., S.A.C., G.R., H.E., M.H.G. and A.M.C.-C. obtained funding for the research. E.C., S.W. and G.R. developed and conducted the analysis with significant support and input from C.L.E. and A.M.C.-C., C.L.E., S.J.H.B., S.A.C., D.W.D., H.E., M.H.G., L.J.G., G.N.H., B.D.M., F.M., T.Y. and A.M.C.-C. contributed to the design and undertaking of the SMART Work and Life trial. EC drafted the manuscript with substantial input from all co-authors. All authors were involved in the critical revision of the manuscript and approve this submitted version. All authors have read and agreed to the published version of the manuscript.

Funding: This study is funded by the NIHR [Public Health Research Programme (project No PR-R5-0213-25004)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The research was also supported by the Leicester Clinical Trials Unit, the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands, and the NIHR Leicester Biomedical Research Centre, which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University, and the University of Leicester.

Institutional Review Board Statement: Ethical approval was obtained from the University of Leicester’s Sub-Committee for Medicine and Biological Sciences (Ref: 14372) and the University of Salford’s Research Enterprise and Engagement ethical approval panel (Ref: HSR1718-039) before the commencement of the study.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data that support the findings of this study are not openly available due to them containing information that could compromise research participant privacy/confidentiality. Requests for participant-level quantitative data and statistical codes should be made to the corresponding author. Data requests will be put forward to members of the original trial management team who will release data on a case-by-case basis.

Acknowledgments: We thank the participants for taking part and all the staff and students that contributed to data collection and data entry. We particularly thank the members of the Data Monitoring and Ethics Committee: Trish Gorely, Rob Copeland, Denise Howel, and the Trial Steering Committee for their advice and support over the course of the study: John Buckley, Daniel Bailey, Charlie Foster, Derrick Bennett, Paul Clark, Leesa Hellings-Lamb. We would also like to thank Vijay Gc who provided valuable advice throughout the project.

Conflicts of Interest: The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

References
1. Dempsey, P.C.; Biddle, S.J.H.; Buman, M.P.; Chastin, S.; Ekelund, U.; Friedenreich, C.M.; Katzmarzyk, P.T.; Leitzmann, M.F.; Stamatakis, E.; Van Der Ploeg, H.P.; et al. New global guidelines on sedentary behaviour and health for adults: Broadening the behavioural targets. Int. J. Behav. Nutr. Phys. Act. 2020, 17, 1–12. [CrossRef] [PubMed]
2. Heron, L.; O’Neill, C.; McAneney, H.; Kee, F.; Tully, M.A. Direct healthcare costs of sedentary behaviour in the UK. J. Epidemiol. Community Health 2019, 73, 625–629. [CrossRef] [PubMed]
3. Stockwell, S.; Trott, M.; Tully, M.; Shin, J.; Barnett, Y.; Butler, L.; McDermott, D.; Schuch, F.; Smith, L. Changes in physical activity and sedentary behaviours from before to during the COVID-19 pandemic lockdown: A systematic review. BMJ Open Sport Exerc. Med. 2021, 7, e000960. [CrossRef] [PubMed]
4. Sallis, R.; Young, D.R.; Tartof, S.Y.; Sallis, J.F.; Sall, J.; Li, Q.; Smith, G.N.; A Cohen, D. Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: A study in 48,440 adult patients. Br. J. Sports Med. 2021, 55, 1099–1105. [CrossRef]
5. Bull, F.C.; Al-Ansari, S.S.; Biddle, S.; Borodulin, K.; Buman, M.P.; Cardon, G.; Carty, C.; Chaput, J.-P.; Chastin, S.; Chou, R.; et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br. J. Sports Med. 2020, 54, 1451–1462. [CrossRef]

6. UK Chief Medical Officers’ Physical Activity Guidelines. Department of Health and Social Care. Report. 2019. Available online: https://www.gov.uk/government/publications/physical-activity-guidelines-uk-chief-medical-officers-report (accessed on 31 January 2022).

7. Edwardson, C.L.; Yates, T.; Biddle, S.J.H.; Davies, M.J.; Dunstan, D.W.; Esliger, D.W.; Gray, L.J.; Jackson, B.; O’Connell, S.E.; Waheed, G.; et al. Effectiveness of the stand more at (SMArT) work intervention: Cluster randomised controlled trial. BMJ 2018, 363, 3870. [CrossRef] [PubMed]

8. Healy, G.N.; Eakin, E.; LaMontagne, A.D.; Owen, N.; Winkler, E.A.; Wiesner, G.; Gunning, L.; Neuhaus, M.; Lawler, S.; Fjeldsoe, B.S.; et al. Reducing sitting time in office workers: Short-term efficacy of a multicomponent intervention. Prev. Med. 2013, 57, 43–48. [CrossRef]

9. Thorp, A.A.; Kingwell, B.A.; Owen, N.; Dunstan, D.W. Breaking up workplace sitting time with intermittent standing bouts improves fatigue and musculoskeletal discomfort in overweight/obese office workers. Occup. Environ. Med. 2014, 71, 765–771. [CrossRef]

10. Henson, J.; Davies, M.J.; Bodicoat, D.H.; Edwardson, C.L.; Gill, J.M.; Stensel, D.J.; Tolfrey, K.; Dunstan, D.W.; Khunti, K.; Yates, T. Breaking Up Prolonged Sitting With Standing or Walking Attenuates the Postprandial Metabolic Response in Postmenopausal Women: A Randomized Acute Study. Diabetes Care 2016, 39, 130–138. [CrossRef]

11. Dunstan, D.W.; Kingwell, B.A.; Larsen, R.; Healy, G.N.; Cerin, E.; Hamilton, M.T.; Shaw, J.E.; Bertovic, D.A.; Zimmet, P.Z.; Salmon, J.; et al. Breaking up prolonged sitting reduces postprandial glucose and insulin responses. Diabetes Care 2012, 35, 976–983. [CrossRef]

12. Thorp, A.A.; Kingwell, B.A.; Sethi, P.; Hammond, L.; Owen, N.; Dunstan, D.W. Alternating bouts of sitting and standing attenuate postprandial glucose responses. Med. Sci. Sports Exerc. 2014, 46, 2053–2061. [CrossRef] [PubMed]

13. Larsen, R.N.; Kingwell, B.A.; Sethi, P.; Cerin, E.; Owen, N.; Dunstan, D.W. Breaking up prolonged sitting reduces resting blood pressure in overweight/obese adults. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 976–982. [CrossRef] [PubMed]

14. McCarthy, M.; Edwardson, C.L.; Davies, M.; Henson, J.; Bodicoat, D.H.; Khunti, K.; Dunstan, D.W.; King, J.A.; Yates, T. Fitness Moderates Glycemic Responses to Sitting and Light Activity Breaks. Med. Sci. Sports Exerc. 2017, 49, 2216–2222. [CrossRef]

15. Crespo, N.C.; Mullan, S.L.; Zeigler, Z.S.; Buman, M.P.; Gaesser, G.A. Effects of Standing and Light-Intensity Walking and Cycling on 24-h Glucose. Med. Sci. Sports Exerc. 2016, 48, 2503–2511. [CrossRef] [PubMed]

16. Wennberg, P.; Boraxbekk, C.-J.; Wheeler, M.; Howard, B.; Dempsey, P.; Lambert, G.; Eikelis, N.; Larsen, R.; Sethi, P.; Ockleston, J.; et al. Acute effects of breaking up prolonged sitting on fatigue and cognition: A pilot study. BMJ Open 2016, 6, e009630. [CrossRef]

17. Zhao, R.; Bu, W.; Chen, Y.; Chen, X. The Dose-Response Associations of Sedentary Time with Chronic Diseases and the Risk for All-Cause Mortality Affected by Different Health Status: A Systematic Review and Meta-Analysis. J. Nutr. Health Aging 2020, 24, 63–70. [CrossRef]

18. Ekelund, U.; Tarp, J.; Steene-Johannessen, J.; Hansen, B.H.; Jefferis, B.; Fagerland, M.W.; Whincup, P.; Diaz, K.M.; Hooker, S.P.; Chernofsky, A.; et al. Dose-response associations between accelerometer measured physical activity and sedentary time and all-cause mortality: Systematic review and harmonised meta-analysis. BMJ 2019, 366, l4570. [CrossRef]

19. Patterson, R.; McNamara, E.; Tainio, M.; De S; Chaput, J.-P.; Chastin, S.; Chou, R.; et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br. J. Sports Med. 2020, 54, 1451–1462. [CrossRef]

20. National Institute of Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013; NICE: London, UK, 2013.

21. National Institute of Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013; NICE: London, UK, 2013.

22. Carpenter, J.R.; Goldstein, H.; Kenward, M.G. REALCOM-IMPUTE Software for Multilevel Multiple Imputation with Mixed Response Types. Available online: http://www.jstatsoft.org/ (accessed on 2 March 2021).
28. Grund, S.; Lüdtke, O.; Robitschek, A. Multiple Imputation of Missing Data for Multilevel Models. Organ. Res. Methods 2008, 21, 111–149. [CrossRef]
29. Edwardson, C.L.; Biddle, S.J.H.; Clarke-Cornwell, A.; Clemen, S.; Davies, M.J.; Dunstan, D.W.; Eborall, H.; Granat, M.H.; Gray, L.J.; Healy, G.N.; et al. A three arm cluster randomised controlled trial to test the effectiveness and cost-effectiveness of the SMART Work & Life intervention for reducing daily sitting time in office workers: Study protocol. BMC Public Health 2018, 18, 1120. [CrossRef]
30. National Health Service (NHS) Improvement. Reference Costs 2018-19. 2018. Available online: https://improvement.nhs.uk/resources/reference-costs/ (accessed on 11 January 2021).
31. Personal Social Services Research Unit (PSSRU). Unit Costs of Health and Social Care 2019. 2019. Available online: https://www.pssru.ac.uk/project-pages/unit-costs/ (accessed on 11 January 2021).
32. Office for National Statistics. Employee Earnings in the UK: 2019. Available online: https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/bulletins/annualsurveyofhoursandearnings/2019 (accessed on 11 January 2021).
33. EuroQol Group. EQ-5D Instruments—EQ-5D. 2020. Available online: https://euroqol.org/eq-5d-instruments/ (accessed on 24 January 2022).
34. Van Hout, B.; Janssen, M.F.; Feng, Y.S.; Kohlmann, T.; Busschbach, J.; Gellici, D.; Lloyd, A.; Scalone, L.; Mphil, P.K.; Pickard, A.S. Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012, 15, 708–715. [CrossRef] [PubMed]
35. Nelder, J.A.; Wedderburn, R.W.M. Generalized Linear Models. J. R. Stat. Soc. Ser. A 1972, 135, 370. [CrossRef]
36. Manca, A.; Hawkins, N.; Sculpher, M.J. Estimating mean QALYs in trial-based cost-effectiveness analysis: The importance of controlling for baseline utility. Health Econ. 2005, 14, 487–496. [CrossRef]
37. Barber, J.; Thompson, S. Multiple regression of cost data: Use of generalised linear models. J. Health Serv. Res. Policy 2004, 9, 197–204. [CrossRef]
38. Gelman, A.; Hill, J. Data Analysis Using Regression and Multilevel/Hierarchical Models. 2006. Available online: https://books.google.com/books?hl=en&lr=&id=c9xLKzZWoz4C&oi=fnd&pg=PR17&dq=Data+Analysis+Using+Regression+and+Multilevel/Hierarchical+Models&ots=bcQbOlKXcb&sig=ipDGgNFzejun81uqwNLdk5Z8Izo (accessed on 28 March 2022).
39. National Institute for Health and Care Excellence. Methods for the Development of NICE Public Health Guidance (Third Edition). 2012. Available online: https://www.nice.org.uk/process/pgm4/resources/methods-for-the-development-of-nice-public-health-guidance-third-edition-pdf-201207967445701 (accessed on 5 October 2020).
40. Janssen, M.F.; Szende, A.; Cabases, J.; Ramos-Goñi, J.M.; Vilagut, G.; König, H.H. Population norms for the EQ-5D-3L: A cross-country analysis of population surveys for 20 countries. Eur. J. Health Econ. 2019, 20, 205–216. [CrossRef]
41. Asaria, M. Health Care Costs in the English NHS: Reference Tables for Average Annual NHS Spend by Age, Sex and Deprivation Group; Working Papers 147cherp; Centre for Health Economics, University of York: York, UK, 2017.
42. National Life Tables: UK—Office for National Statistics. Available online: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferenceatables (accessed on 3 March 2021).
43. Cobiac, L.J.; Vos, T.; Barendregt, J.J. Cost-Effectiveness of Interventions to Promote Physical Activity: A Modelling Study. PLoS Med. 2009, 6, e1000110. [CrossRef] [PubMed]
44. GC, V.S.; Suhrcke, M.; Hardeman, W.; Sutton, S.; Wilson, E.C.F. Cost-Effectiveness and Value of Information Analysis of Brief Interventions to Promote Physical Activity in Primary Care. Value Health 2018, 21, 18–26. [CrossRef] [PubMed]
45. Jacobs-van der Bruggen, M.A.; Bos, G.; Beemelmans, W.J.; Hoogenveen, R.T.; Vijgen, S.M.; Baan, C.A. Lifestyle Interventions Are Cost-Effective in People With Different Levels of Diabetes Risk Results from a modeling study. Diabetes Care 2007, 30, 128–134. [CrossRef] [PubMed]
46. Over, E.A.B.; Wendel-Vos, G.C.W.; van den Berg, M.; Reenen, H.H.H.; Tariq, L.; Hoogenveen, R.T.; van Baal, P.H. Cost-effectiveness of counseling and pedometer use to increase physical activity in the Netherlands: A modeling study. Cost Eff. Resour. Alloc. 2012, 10, 1–7. [CrossRef] [PubMed]
47. Gao, L.; Flego, A.; Dunstan, D.W.; Winkler, E.A.; Healy, G.N.; Eakin, E.G.; Willenberg, L.; Owen, N.; Lamontagne, A.D.; Lal, A.; et al. Economic evaluation of a randomized controlled trial of an intervention to reduce office workers’ sitting time: The “Stand up Victoria” trial. Scand. J. Work Environ. Health 2018, 44, 503–511. [CrossRef]
48. Rubin, D. Multiple Imputation for Nonresponse in Surveys; John Wiley & Sons: New York, NY, USA, 2004.
49. Von Hippel, P.T. How Many Imputations Do You Need? A Two-stage Calculation Using a Quadratic Rule. Social. Methods Res. 2018, 49, 699–718. [CrossRef]
50. Briggs, A.; Sculpher, M.; Claxton, K. Decision Modelling for Health Economic Evaluation; Oxford University Press: Oxford, UK, 2006.
51. Claxton, K.; Martin, S.; Soares, M.; Rice, N.; Spackman, E.; Hinde, S.; Devlin, N.; Smith, P.C.; Sculpher, M. Methods for the estimation of the National Institute for Health and care excellence cost-effectiveness threshold. Health Technol. Assess. 2015, 19, 1–503. [CrossRef]
52. Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research | OHE. Available online: https://www.ohe.org/publications/issues-surrounding-estimation-opportunity-cost-adopting-new-health-care-technology (accessed on 22 June 2020).
53. The Green Book (2020)—GOV.UK. 2020. Available online: https://www.gov.uk/government/publications/the-green-book-appraisal-and-evaluation-in-central-government/the-green-book-2020 (accessed on 27 February 2022).

54. Walker, S.; Griffin, S.; Asaria, M.; Tsuchiya, A.; Sculpher, M. Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers. *Appl. Health Econ. Health Policy* **2019**, *17*, 577–590. [CrossRef]

55. Michaud, T.L.; You, W.; A Estabrooks, P.; Leonard, K.; A Rydell, S.; Mullane, S.L.; A Pereira, M.; Buman, M.P. Cost and cost-effectiveness of the “Stand and Move at Work” multicomponent intervention to reduce workplace sedentary time and cardiometabolic risk. *Scand. J. Work Environ. Health* **2022**, *48*, 399–409. [CrossRef]

56. Gao, L.; Nguyen, P.; Dunstan, D.; Moodie, M. Are office-based workplace interventions designed to reduce sitting time cost-effective primary prevention measures for cardiovascular disease? A systematic review and modelled economic evaluation. *Int. J. Environ. Res. Public Health* **2019**, *16*, 834. [CrossRef]

57. Ben, J.; Jelsma, J.G.; Renaud, L.R.; Huysmans, M.A.; van Nassau, F.; van der Beek, A.J.; van der Ploeg, H.P.; van Dongen, J.M.; Bosmans, J.E. Cost-Effectiveness and Return-on-Investment of the Dynamic Work Intervention Compared With Usual Practice to Reduce Sedentary Behavior. *J. Occup. Environ. Med.* **2020**, *62*, e449–e456. [CrossRef] [PubMed]

58. Nguyen, P.; Le, L.K.D.; Ananthapavan, J.; Gao, L.; Dunstan, D.W.; Moodie, M. Economics of sedentary behaviour: A systematic review of cost of illness, cost-effectiveness, and return on investment studies. *Prev. Med.* **2022**, *156*, 106964. [CrossRef] [PubMed]